ClinVar Miner

Submissions for variant NM_000303.3(PMM2):c.484C>T (p.Arg162Trp) (rs104894526)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000008148 SCV000220327 likely pathogenic Congenital disorder of glycosylation, type Ia 2014-05-16 criteria provided, single submitter literature only
GeneDx RCV000403363 SCV000329703 pathogenic not provided 2015-12-31 criteria provided, single submitter clinical testing The R162W pathogenic variant in the PMM2 gene has been reported previously in the compound heterozygous state, opposite of a second PMM2 pathogenic variant in many patients with congenital disorder of glycosylation, type 1a, more recently known as PMM2-CDG (Quelhas et al., 2007; Matthijs et al., 1997; Perez et al., 2011). The R162W variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The R162W variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is not conserved. Functional studies demonstrate the R162W variant protein is less stable than the wild type and has reduced enzyme activity (Yuste-Checa et al., 2015). We interpret R162W as a pathogenic variant.
SIB Swiss Institute of Bioinformatics RCV000008148 SCV000803453 likely pathogenic Congenital disorder of glycosylation, type Ia 2018-05-31 criteria provided, single submitter curation This variant is interpreted as a Likely Pathogenic, for Congenital disorder of glycosylation, type Ia, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PM3 => For recessive disorders, detected in trans with a pathogenic variant (PMID:21541725). PS3 => Well-established functional studies show a deleterious effect (PMID:21541725,10386614).
Invitae RCV000008148 SCV000829571 pathogenic Congenital disorder of glycosylation, type Ia 2018-12-20 criteria provided, single submitter clinical testing This sequence change replaces arginine with tryptophan at codon 162 of the PMM2 protein (p.Arg162Trp). The arginine residue is moderately conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is present in population databases (rs104894526, ExAC 0.006%). This variant has been observed in the compound-heterozygous state in several individuals affected with congenital disorder of glycosylation type 1a (PMID: 9140401, 17166182, 9497260, 21541725, 15844218). ClinVar contains an entry for this variant (Variation ID: 7709). Experimental studies have shown that this missense change impairs protein stability and enzyme activity (PMID: 26014514, 10386614). For these reasons, this variant has been classified as Pathogenic.
OMIM RCV000008148 SCV000028353 pathogenic Congenital disorder of glycosylation, type Ia 1997-05-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.